MedKoo Cat#: 471102 | Name: PF-04827736
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PF-04827736 is a non-brain penetrant potent and selective inhibitor of PDE1

Chemical Structure

PF-04827736
CAS#Unknown

Theoretical Analysis

MedKoo Cat#: 471102

Name: PF-04827736

CAS#: Unknown

Chemical Formula: C17H21N5O2

Exact Mass: 327.1700

Molecular Weight: 327.39

Elemental Analysis: C, 62.37; H, 6.47; N, 21.39; O, 9.77

Price and Availability

Size Price Availability Quantity
5mg USD 475.00 2 Weeks
25mg USD 900.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
PF-04827736; PF04827736; PF 04827736
IUPAC/Chemical Name
(S)-7,8-dimethoxy-N-(1-(5-methyl-1H-pyrazol-3-yl)propan-2-yl)quinazolin-4-amine
InChi Key
JTROLECZHRVLFM-JTQLQIEISA-N
InChi Code
InChI=1S/C17H21N5O2/c1-10(7-12-8-11(2)21-22-12)20-17-13-5-6-14(23-3)16(24-4)15(13)18-9-19-17/h5-6,8-10H,7H2,1-4H3,(H,21,22)(H,18,19,20)/t10-/m0/s1
SMILES Code
CC1=CC(C[C@@H](NC2=C3C=CC(OC)=C(OC)C3=NC=N2)C)=NN1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 327.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Le, M. L., Jiang, M. Y., Han, C., Yang, Y. Y., & Wu, Y. (2022). PDE1 inhibitors: a review of the recent patent literature (2008-present). Expert Opinion on Therapeutic Patents, 32(4), 423-439. Zhu, Z., Tang, W., Qiu, X., Xin, X., & Zhang, J. (2023). Advances in targeting Phosphodiesterase 1: From mechanisms to potential therapeutics. European Journal of Medicinal Chemistry, 115967. Brzezinska, P., & Maurice, D. H. (2019). An EPAC1/PDE1C-signaling axis regulates formation of leading-edge protrusion in polarized human arterial vascular smooth muscle cells. Cells, 8(12), 1473. Roks, A. J. (2022). Phosphodiesterase-1 in the cardiovascular system. Cellular signalling, 92, 110251.